An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Trial Profile

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Insulin (Primary) ; Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Biodel
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2012 Planned patient number is changed from 222 to 400 as reported by European Clinical Trials Database record (Extension trial; EudraCT2007-006084-73).
    • 21 Apr 2012 Planned patient number is changed from 222 to 400 as reported by European Clinical Trials Database record (Extension trial; EudraCT2007-006084-73).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top